Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy

Muscle and Nerve

Volumn 38, Issue 2, 2008, Pages 1036-1045

  Harbo, Thomas ^a   Andersen, Henning ^a   Jakobsen, Johannes ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Axonal loss; Chronic inflammatory demyelinating polyradiculoneuropathy; Compound muscle action potential; Muscle strength; Pathophysiology

Indexed keywords

IMMUNOGLOBULIN; STEROID;

ADULT; AGED; AMPLITUDE DECAY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISTAL LATENCY; DYNAMOMETRY; ELECTROPHYSIOLOGY; FEMALE; HUMAN; LATENT PERIOD; MALE; MEDIAN NERVE; MINIMAL F WAVE LATENCY; MUSCLE ACTION POTENTIAL; MUSCLE LENGTH; MUSCLE STRENGTH; MUSCLE WEAKNESS; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NERVE STIMULATION; NEUROPATHY; PARAMETER; PATHOPHYSIOLOGY; PERONEUS NERVE; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSORY DYSFUNCTION; SENSORY EVALUATION; SURAL NERVE; TIBIAL NERVE; ULNAR NERVE;

ACTION POTENTIALS; ADULT; AGED; ELECTRIC STIMULATION; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH DYNAMOMETER; MUSCLE, SKELETAL; NEURAL CONDUCTION; PERIPHERAL NERVES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; REACTION TIME; RETROSPECTIVE STUDIES; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX;

EID: 49449090042     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21000     Document Type: Article

References (46)

1. Aadahl M, Jorgensen T. Validation of a new sell-report instrument for measuring physical activity. Med Sci Sports Exerc 2003;35:1196-1202.
2. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617-618.
3. Albers JW. Clinical neurophysiology of generalized polyneuropathy. J Clin Neurophysiol 1993;10:149-166.
4. Asahina M, Kuwabara S, Nakajima M, Yamada T. Demyelinating polyneuropathy with preferentially-proximal involvement. Clin Neurol Neurosurg 1998;100:53-55.
5. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
6. Berciano J, Figols J, Garcia A, Calle E, Illa I, Lafarga M, et al. Fulminant Guillain-Barre syndrome with universal inexcitability of peripheral nerves: a clinicopathological study. Muscle Nerve 1997;20:846-857.
7. Bouchard C, Lacroix C, Plante V, Adams D, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999;52:498-503.
8. Bromberg MB, Albers JW. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 1993;16:262-266.
9. Buchthal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain 1977;100(Pt 1):41-66.
10. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22-S31.
11. Dyck PJ. Invited review: limitations in predicting pathologic abnormality of nerves from the EMG examination. Muscle Nerve 1990;13:371-375.
12. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229-239.
13. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-637.
14. Dyck PJ, Litchy WJ, Daube JR, Harper CM, Dyck PJ, Davies J, et al. Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility, and concordance with impairment. Muscle Nerve 2003;27:202-210.
15. Dyck PJ, O'Brien PC, Kosanke JL, Gillen DA, Karnes JL. A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold. Neurology 1993;43:1508-1512.
16. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-596.
17. Erdmann PG, van Meeteren NL, Kalmijn S, Wokke JH, Helders PJ, Van den Berg LH. Functional health status of patients with chronic inflammatory neuropathies. J Peripher Nerv Syst 2005;10:181-189.
18. Falck B, Stålberg E, Bitsch A. Sensory nerve conduction studies with surface electrodes. Methods Clin Neurophysiol 1994;5:1-20.
19. Feasby TE, Brown WF, Gilbert JJ, Hahn AF. The pathological basis of conduction block in human neuropathies. J Neurol Neurosurg Psychiatry 1985;48:239-244.
20. Franssen H, Notermans NC. Length dependence in polyneuropathy associated with IgM gammopathy. Ann Neurol 2006;59:365-371.
21. Hughes R, Bensa S, Willison H, Van den BP, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
22. Iijima M, Yamamoto M, Hirayama M, Tanaka F, Katsuno M, Mori K, et al. Clinical and electrophysiologic correlates of Mg responsiveness in CIDP. Neurology 2005;64:1471-1475.
23. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
24. Krarup C, Trojaborg W. Sensory pathophysiology in chronic acquired demyelinating neuropathy. Brain 1996;119(Pt 1):257-270.
25. Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006;77:66-70.
26. Kuwabara S, Ogawara K, Misawa S, Mori M, Hattori T. Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002;72:37-42.
27. Logigian EL, Kelly JJ, Jr., Adelman LS. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 1994;17:1010-1020.
28. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.
29. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2003;74:99-104.
30. Molenaar DS, Vermeulen M, de Visser M, de Haan R. Impact of neurologic signs and symptoms on functional status in peripheral neuropathies. Neurology 1999;52:151-156.
31. Mygland A, Monstad P, Vedeler C. Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2005;31:589-593.
32. Notermaus NC, Wokke JH, Lokhorst HM, Franssen H, van der GY, Jennekens FG. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994;117(Pt 6):1385-1393.
33. Rajabally YA, Narasimhan M. The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2007;118:1999-2004.
34. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 2006;16:293-303.
35. Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000;21:31-37.
36. Stålberg E, Falck B. Clinical motor nerve conduction studies. Methods Clin Neurophysiol 1993;4:61-80.
37. Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol 2005;116:1571-1580.
38. Tankisi H, Pugdahl K, Johnsen B, Fuglsang-Frederiksen A. Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies. Clin Neurophysiol 2007;118:2383-2392.
39. Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2006;77:743-747.
40. Van Asseldonk JT, Van den Berg LH, Van den Berg-Vos RM, Wieneke GH, Wokke JH, Franssen H. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 2003;126:186-198.
41. Van Asseldonk JT, Van den Berg LH, Wieneke GH, Wokke JH, Franssen H. Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain 2006;129:2447-2460.
42. van der Meche FG, Meulstee J, Kleyweg RP. Axonal damage in Guillain-Barre syndrome. Muscle Nene 1991;14:997-1002.
43. van der Meche FG, Vermeulen M, Busch HF. Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy. Brain 1989;112(Pt 6):1563-1571.
44. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
45. Vucic S, Black K, Baldassari LE, Tick Chong PS, Dawson KT, Cros D. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophysiol 2007;118:1980-1984.
46. Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63:1264-1269.